Alector — Q3 2026 Earnings Summary

Financial Performance

• Received a $100 million upfront payment from Genentech under the new global license agreement.
• Eligible for up to $1.17 billion in additional milestone payments contingent on the achievement of development, regulatory, and commercial milestones.
• Eligible for tiered royalties on net sales of the licensed product.
• The partnership extends the company's cash runway into 2029.

Guidance and Future Outlook

• Plans to advance its fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer's patients.
• Intends to move its subcutaneously delivered, brain-enabled Tau siRNA and alpha-synuclein siRNA programs through IND-enabling studies and to IND filings.
• Genentech will assume responsibility for development, regulatory, manufacturing, and commercialization of the AL050 program across all indications.

Business Segments and Product Lines

• Entered into an exclusive global licensing agreement with Genentech for AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by the Alector Brain Carrier (ABC).
• AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson's Disease, particularly in carriers of GBA1 mutations.
• The therapy combines an Alector-engineered GCase (optimized for greater enzymatic activity and longer half-life) with the ABC platform to transport therapeutics across the blood-brain barrier.
• Retains full ownership of the ABC platform and rights to apply it across its wholly owned pipeline.
• Scheduled to host a scientific webinar on October 13, 2026, focusing on AL137 (brain-enabled anti-Aβ antibody), AL164 (tau siRNA program), and AL062 (alpha-synuclein siRNA program).

Market and Competitive Landscape

• Parkinson's Disease is identified as one of the fastest-growing neurological conditions worldwide.
• No currently approved therapy addresses the underlying enzyme deficiency associated with GCase deficiency.
• Genentech is described as having a long-standing commitment to Parkinson's Disease.

Risks and Challenges

• Development of AL050 and other pipeline programs faces risks and uncertainties, including potential delays in clinical trials, regulatory approval, and commercialization.
• Forward-looking statements regarding business plans, product candidates, and financial guidance are subject to numerous risks and uncertainties detailed in the company's SEC filings (Form 10-K and Form 10-Q).
• Actual results may differ materially from forward-looking statements due to factors such as the success of preclinical studies, clinical trial outcomes, and the achievement of milestones.

Management Commentary and Tone

• CEO Arnon Rosenthal, Ph.D., stated that the partnership with Genentech is ideal due to their long-standing commitment to Parkinson's Disease as the program moves toward the clinic.
• Rosenthal highlighted that the challenge in treating GCase deficiency involves both engineering an enzyme with optimal activity and durability and successfully delivering it to the brain.
• Boris L. Zaïtra, Head of Roche Corporate Business Development, noted that the partnership aims to delay or halt the progression of Parkinson's so patients can maintain and prolong their independence.

Other Key Points

• Alector grants Genentech exclusive rights to develop and commercialize AL050 worldwide.
• The agreement covers all indications for the AL050 program.
• Alector's proprietary ABC platform aims to enhance delivery of therapeutics, achieve deeper brain penetration, and improve patient outcomes while reducing costs.
• The press release includes standard forward-looking statement disclaimers under the Private Securities Litigation Reform Act of 1995.